An optimised method for the production of MERS-CoV spike expressing viral pseudotypes

MethodsX

Volumn 2, Issue , 2015, Pages 379-384

  Grehan, K ^a   Ferrara, F ^a   Temperton, N ^a  

^a MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

Lentiviral pseudotype; MERS coronavirus; Virus neutralisation

Indexed keywords

VIRUS GLYCOPROTEIN; VIRUS SPIKE PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOGENICITY; LENTIVIRINAE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; SEROLOGY; VIRAL TROPISM; VIRUS EXPRESSION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS SPIKE; VIRUS TITRATION;

EID: 84944891894     PISSN: None     EISSN: 22150161     Source Type: Journal    
DOI: 10.1016/j.mex.2015.09.003     Document Type: Article

References (12)

1. E. Molesti, E. Wright, C. Terregino, R. Rahman, G. Cattoli, and N.J. Temperton Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies J. Immunol. Res. 4579 2014 32
2. Q. Wang, J. Qi, Y. Yuan, Y. Xuan, P. Han, Y. Wan, W. Ji, Y. Li, Y. Wu, J. Wang, A. Iwamoto, P.C.Y. Woo, K.-Y. Yuen, J. Yan, G. Lu, and G.F. Gao Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26 Cell Host Microbe 16 2014 328 337
3. G. Zhao, L. Du, C. Ma, Y. Li, L. Li, V.K.M. Poon, L. Wang, F. Yu, B. Zheng, S. Jiang, and Y. Zhou A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV Virol. J. 10 2013 1 8
4. S. Mather, S. Scott, N. Temperton, E. Wright, B. King, and J. Daly Current progress with serological assays for exotic emerging/re-emerging viruses Future Virol. 8 2013 745 755
5. Z. Qian, S.R. Dominguez, and K.V. Holmes Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation PLOS ONE 8 2013
6. S. Scott, E. Molesti, N. Temperton, and F. Ferrara The use of equine influenza pseudotypes for serological screening J. Mol. Genet. Med. 6 2012 304 308
7. N.J. Temperton, P.K. Chan, G. Simmons, M.C. Zambon, R.S. Tedder, Y. Takeuchi, and R.A. Weiss Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes Emerg. Infect. Dis. 11 2005 411 416
8. G.W. Carnell, F. Ferrara, K. Grehan, C.P. Thompson, and N.J. Temperton Pseudotype-based neutralization assays for influenza: a systematic analysis Front. Immunol. 6 2015 1 17
9. R.H. Kutner, X.-Y. Zhang, and J. Reiser Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors Nat. Protoc. 4 2009 495 505
10. F. Ferrara, E. Molesti, E. Böttcher-Friebertshäuser, G. Cattoli, S.D. Scott, and N.J. Temperton The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes J. Mol. Med. Genet. Med. 7 2013 309 314
11. R. Zufferey, T. Dull, R.J. Mandel, A. Bukovsky, D. Quiroz, L. Naldini, and D. Trono Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery J. Virol. 72 1998 9873 9880
12. R. Zufferey, D. Nagy, R.J. Mandel, L. Naldini, and D. Trono Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo Nat. Biotechnol. 15 1997 871 875